STOCK TITAN

Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio chief scientific officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The Form 4 shows nine sales of Belite Bio ADS on April 22, 2026, at weighted average prices ranging from about $165.64 to $173.16. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Each ADS represents one ordinary share of Belite Bio.

Positive

  • None.

Negative

  • None.
Insider MATA NATHAN L.
Role Chief Scientific Officer
Sold 1,000 shs ($170K)
Type Security Shares Price Value
Sale American depositary share 31 $165.701 $5K
Sale American depositary share 20 $166.32 $3K
Sale American depositary share 141 $167.4206 $24K
Sale American depositary share 101 $168.6355 $17K
Sale American depositary share 105 $169.5236 $18K
Sale American depositary share 75 $170.5833 $13K
Sale American depositary share 257 $171.615 $44K
Sale American depositary share 249 $172.4901 $43K
Sale American depositary share 21 $173.041 $4K
Holdings After Transaction: American depositary share — 11,635 shares (Direct, null)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $165.64 to $165.71. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $166.19 to $166.71. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $167.08 to $167.86. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $168 to $168.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $169.08 to $169.78. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $170 to $170.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $171.01 to $171.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $172 to $172.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $173 to $173.16. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Shares sold 1,000 ADS Total American depositary shares sold on April 22, 2026
Price range low $165.64 per ADS Lowest weighted average sale price bucket disclosed
Price range high $173.16 per ADS Highest weighted average sale price bucket disclosed
Rule 10b5-1 plan adoption date December 10, 2025 Plan governing the April 22, 2026 sales
Number of transactions 9 sales Open-market sale entries reported in Form 4
ADS to ordinary share ratio 1 ADS : 1 ordinary share Each ADS represents one ordinary share
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share"
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MATA NATHAN L.

(Last)(First)(Middle)
7708 MARKER ROAD

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)04/22/2026S(2)31D$165.701(3)11,635D
American depositary share(1)04/22/2026S(2)20D$166.32(4)11,615D
American depositary share(1)04/22/2026S(2)141D$167.4206(5)11,474D
American depositary share(1)04/22/2026S(2)101D$168.6355(6)11,373D
American depositary share(1)04/22/2026S(2)105D$169.5236(7)11,268D
American depositary share(1)04/22/2026S(2)75D$170.5833(8)11,193D
American depositary share(1)04/22/2026S(2)257D$171.615(9)10,936D
American depositary share(1)04/22/2026S(2)249D$172.4901(10)10,687D
American depositary share(1)04/22/2026S(2)21D$173.041(11)10,666D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. Represents the weighted average price of shares sold at prices that ranged from $165.64 to $165.71. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $166.19 to $166.71. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. Represents the weighted average price of shares sold at prices that ranged from $167.08 to $167.86. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. Represents the weighted average price of shares sold at prices that ranged from $168 to $168.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. Represents the weighted average price of shares sold at prices that ranged from $169.08 to $169.78. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
8. Represents the weighted average price of shares sold at prices that ranged from $170 to $170.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
9. Represents the weighted average price of shares sold at prices that ranged from $171.01 to $171.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
10. Represents the weighted average price of shares sold at prices that ranged from $172 to $172.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
11. Represents the weighted average price of shares sold at prices that ranged from $173 to $173.16. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Nathan L. Mata04/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) report for Nathan L. Mata?

Belite Bio reported that chief scientific officer Nathan L. Mata sold 1,000 American depositary shares in open-market trades. The sales occurred on April 22, 2026, across multiple price buckets, according to the company’s Form 4 insider filing.

At what prices did Nathan L. Mata sell Belite Bio (BLTE) ADS?

Nathan L. Mata’s trades used weighted average prices ranging from about $165.64 to $173.16 per American depositary share. Footnotes explain each weighted average covers several individual sales within the stated price range.

Was the Belite Bio (BLTE) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted by Nathan L. Mata on December 10, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing.

How many individual transactions did the Belite Bio (BLTE) Form 4 include?

The Form 4 lists nine separate open-market sale transactions in Belite Bio American depositary shares. Together they total 1,000 ADS, all executed on April 22, 2026, according to the transaction summary in the filing.

What does each Belite Bio (BLTE) American depositary share represent?

Each Belite Bio American depositary share (ADS) represents one ordinary share of the company. This 1:1 relationship is disclosed in the Form 4 footnotes and helps investors translate ADS activity into underlying ordinary share exposure.